Dopamine D2 receptor is involved in alleviation of type II collagen-induced arthritis in mice

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Lu, Jian Hua ^a   Liu, Yi Qian ^a   Deng, Qiao Wen ^a   Peng, Yu Ping ^a   Qiu, Yi Hua ^a  

^a NANTONG MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; DOPAMINE 2 RECEPTOR; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 22; QUINPIROLE; TRANSFORMING GROWTH FACTOR BETA; DOPAMINE 1 RECEPTOR; DRD1A PROTEIN, MOUSE; DRD2 PROTEIN, MOUSE; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CHICKEN; CONTROLLED STUDY; DOWN REGULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH17 CELL; UPREGULATION; WILD TYPE; ANIMAL; ANKLE; BIOSYNTHESIS; DISEASE MODEL; EXPERIMENTAL ARTHRITIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; RHEUMATOID ARTHRITIS;

ANIMALS; ANKLE JOINT; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-17; INTERLEUKINS; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84949987082     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/496759     Document Type: Article

References (51)

1. F. R. Buttarelli, A. Fanciulli, C. Pellicano, and F. E. Pontieri, "The dopaminergic system in peripheral blood lymphocytes: From physiology to pharmacology and potential applications to neuropsychiatric disorders," Current Neuropharmacology, vol. 9, no. 2, pp. 278-288, 2011.
2. F.Mignini,M. Sabbatini,M. Capacchietti et al., "T-cell subpopulations express a different pattern of dopaminergic markers in intra-and extra-thymic compartments," Journal of Biological Regulators and Homeostatic Agents, vol. 27, no. 2, pp. 463-475, 2013.
3. F.Mignini,D. Tomassoni, E. Traini, and F. Amenta, "Dopamine, vesicular transporters and dopamine receptor expression and localization in rat thymus and spleen," Journal of Neuroimmunology, vol. 206, no. 1-2, pp. 5-13, 2009.
4. J.-L. Jiang, Y.-P. Peng, Y.-H. Qiu, and J.-J. Wang, "Effect of endogenous catecholamines on apoptosis of Con A-activated lymphocytes of rats," Journal of Neuroimmunology, vol. 192, no. 1-2, pp. 79-88, 2007.
5. J.-L. Jiang, Y.-P. Peng, Y.-H. Qiu, and J.-J. Wang, "Adrenoreceptor-coupled signal-transduction mechanisms mediating lymphocyte apoptosis Induced by endogenous catecholamines," Journal of Neuroimmunology, vol. 213, no. 1-2, pp. 100-111, 2009.
6. Y. Huang, A.-W. Qiu, Y.-P. Peng, Y. Liu, H.-W. Huang, and Y.-H. Qiu, "Roles of dopamine receptor subtypes in mediating modulation of T lymphocyte function," Neuroendocrinology Letters, vol. 31, no. 6, pp. 782-791, 2010.
7. Y. Liu, Y. Huang, X.-Q. Wang, Y.-P. Peng, and Y.-H. Qiu, "Effect of tyrosine hydroxylase gene silencing in CD4+ T lymphocytes on differentiation and function of helper T cells," Neuroendocrinology Letters, vol. 33, no. 6, pp. 643-650, 2012.
8. H.-W. Huang, J.-L. Tang, X.-H. Han, Y.-P. Peng, and Y.-H. Qiu, "Lymphocyte-derived catecholamines induce a shift of Th1/Th2 balance toward Th2 polarization," NeuroImmunoModulation, vol. 20, no. 1, pp. 1-8, 2013.
9. D. Vallone, R. Picetti, and E. Borrelli, "Structure and function of dopamine receptors," Neuroscience and Biobehavioral Reviews, vol. 24, no. 1, pp. 125-132, 2000.
10. J.-A. Girault and P. Greengard, "The neurobiology of dopamine signaling," Archives of Neurology, vol. 61, no. 5, pp. 641-644, 2004.
11. R. Pivonello, D. Ferone, G. Lombardi, A. Colao, S. W. J. Lamberts, and L. J. Hofland, "Novel insights in dopamine receptor physiology," European Journal of Endocrinology, vol. 156, no. 1, pp. S13-S21, 2007.
12. L. Santambrogio, M. Lipartiti, A. Bruni, and R. Dal Toso, "Dopamine receptors on human T-and B-lymphocytes," Journal of Neuroimmunology, vol. 45, no. 1-2, pp. 113-119, 1993.
13. F. McKenna, P. J. McLaughlin, B. J. Lewis et al., "Dopamine receptor expression on human T-and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: A flow cytometric study," Journal of Neuroimmunology, vol. 132, no. 1-2, pp. 34-40, 2002.
14. M. C. Ghosh, A. C. Mondal, S. Basu et al., "Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells," International Immunopharmacology, vol. 3, no. 7, pp. 1019-1026, 2003.
15. Y. Watanabe, T. Nakayama, D. Nagakubo et al., "Dopamine selectively induces migration and homing of naive CD8+ T cells via dopamine receptor D3," Journal of Immunology, vol. 176, no. 2, pp. 848-856, 2006.
16. M. Cosentino, A. M. Fietta, M. Ferrari et al., "Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop," Blood, vol. 109, no. 2, pp. 632-642, 2007.
17. K. Nakano, T. Higashi, K. Hashimoto, R. Takagi, Y. Tanaka, and S. Matsushita, "Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: Preventive and therapeutic effects on experimental autoimmune encephalomyelitis," Biochemical and Biophysical ResearchCommunications, vol. 373, no. 2, pp. 286-291, 2008.
18. J. Kipnis,M. Cardon, H. Avidan et al., "Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: Implications for neurodegeneration," The Journal of Neuroscience, vol. 24, no. 27, pp. 6133-6143, 2004.
19. M. J. Besser, Y. Ganor, and M. Levite, "Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNF-alpha or both," Journal of Neuroimmunology, vol. 169, no. 1-2, pp. 161-171, 2005.
20. N. C. Walsh and E. M. Gravallese, "Bone loss in inflammatory arthritis: Mechanisms and treatment strategies," Current Opinion in Rheumatology, vol. 16, no. 4, pp. 419-427, 2004.
21. G. M. Guidelli, T. Barskova, M. G. Brizi et al., "One year in review: Novelties in the treatment of rheumatoid arthritis," Clinical and Experimental Rheumatology, vol. 33, no. 1, pp. 102-108, 2015.
22. J.-S. Park, S.-K. Kwok, M.-A. Lim et al., "STA-21, a promising STAT-3 inhibitor that reciprocally regulates Th17 and Treg cells, inhibits osteoclastogenesis in mice and humans and alleviates autoimmune inflammation in an experimental model of rheumatoid arthritis," Arthritis and Rheumatology, vol. 66, no. 4, pp. 918-929, 2014.
23. L. E. Harrington, R. D. Hatton, P. R.Mangan et al., "Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages," Nature Immunology, vol. 6, no. 11, pp. 1123-1132, 2005.
24. H. Park, Z. Li, X. O. Yang et al., "A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17," Nature Immunology, vol. 6, no. 11, pp. 1133-1141, 2005.
25. S. K. Lundy, S. Sarkar, L. A. Tesmer, and D. A. Fox, "Cells of the synovium in rheumatoid arthritis. T lymphocytes," Arthritis Research &Therapy, vol. 9, no. 1, article 202, 2007.
26. L. A. Tesmer, S. K. Lundy, S. Sarkar, and D. A. Fox, "Th17 cells in human disease," Immunological Reviews, vol. 223, no. 1, pp. 87-113, 2008.
27. M. E. Morgan, R. Flierman, L. M. Van Duivenvoorde et al., "Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells," Arthritis and Rheumatism, vol. 52, no. 7, pp. 2212-2221, 2005.
28. S. Sarkar andD.A. Fox, "RegulatoryTcell defects in rheumatoid arthritis," Arthritis & Rheumatism, vol. 56, no. 3, pp. 710-713, 2007.
29. S. Sakaguchi, "Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and nonself," Nature Immunology, vol. 6, no. 4, pp. 345-352, 2005.
30. L. T. Nguyen, J. Jacobs, D. Mathis, and C. Benoist, "Where FoxP3-dependent regulatory T cells impinge on the development of inflammatory arthritis," Arthritis & Rheumatism, vol. 56, no. 2, pp. 509-520, 2007.
31. Q. Niu, B. Cai, Z.-C. Huang, Y.-Y. Shi, and L.-I. Wang, "DisturbedTh17/Treg balance in patientswith rheumatoid arthritis," Rheumatology International, vol. 32, no. 9, pp. 2731-2736, 2012.
32. W.Wang, S. Shao, Z. Jiao, M. Guo, H. Xu, and S. Wang, "The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis," Rheumatology International, vol. 32, no. 4, pp. 887-893, 2012.
33. J.-S. Park, M.-A. Lim, M.-L. Cho et al., "P53 controls autoimmune arthritis via STAT-mediated regulation of the Th17 cell/treg cell balance in mice," Arthritis and Rheumatism, vol. 65, no. 4, pp. 949-959, 2013.
34. D.D. Brand, A. H. Kang, and E. F. Rosloniec, "Themouse model of collagen-induced arthritis," Methods in Molecular Medicine, vol. 102, pp. 295-312, 2004.
35. J.-K. Yi, H.-J. Kim, D.-H. Yu et al., "Regulation of inflammatory responses and fibroblast-like synoviocyte apoptosis by calcineurin-binding protein 1 in mice with collagen-induced arthritis," Arthritis & Rheumatism, vol. 64, no. 7, pp. 2191-2200, 2012.
36. X.-Y. Zhao, S.-W. Cui, X.-Q. Wang, Y.-P. Peng, and Y.-H. Qiu, "Tyrosine hydroxylase expression in CD4+ T cells is associated with joint inflammatory alleviation in collagen type II-induced arthritis," Rheumatology International, vol. 33, no. 10, pp. 2597-2605, 2013.
37. I. Kang, W. W. Lee, and Y.-S. Lee, "Modulation of collageninduced arthritis by IL-4 and dexamethasone: The synergistic effect of IL-4 and dexamethasone on the resolution of CIA," Immunopharmacology, vol. 49, no. 3, pp. 317-324, 2000.
38. Y. O. Jung, S.-Y. Min, M.-L. Cho et al., "CD8α+ dendritic cells enhance the antigen-specific CD4+ T-cell response and accelerate development of collagen-induced arthritis," Immunology Letters, vol. 111, no. 2, pp. 76-83, 2007.
39. Y. Sakaguchi, H. Shirahase, A. Ichikawa, M. Kanda, Y. Nozaki, and Y. Uehara, "Effects of selective iNOS inhibition on type II collagen-induced arthritis in mice," Life Sciences, vol. 75, no. 19, pp. 2257-2267, 2004.
40. L. Svelander, H. Erlandsson-Harris, L. Astner et al., "Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice," European Journal of Pharmacology, vol. 613, no. 1-3, pp. 155-162, 2009.
41. Y. R. Lee, J. K.Hwang, H. S. Lee et al., "SPA0355, a thiourea analogue, inhibits inflammatory responses and joint destruction in fibroblast-like synoviocytes and mice with collagen-induced arthritis," British Journal of Pharmacology, vol. 164, no. 2, pp. 794-806, 2011.
42. N. A. Shahabi, K. M. Linner, and B. M. Sharp, "Murine splenocytes express a naloxone-insensitive binding site for α-endorphin," Endocrinology, vol. 126, no. 3, pp. 1442-1448, 1990.
43. A. Bernard, C. Meier, M. Ward et al., "Packed red blood cells suppress T-cell proliferation through a process involving cellcell contact," Journal of Trauma-Injury, Infection and Critical Care, vol. 69, no. 2, pp. 320-329, 2010.
44. L. Dong, X. Wang, J. Tan et al., "Decreased expression of microRNA-21 correlates with the imbalance of Th17 and Treg cells in patients with rheumatoid arthritis," Journal of Cellular and Molecular Medicine, vol. 18, no. 11, pp. 2213-2224, 2014.
45. M. Samson, S. Audia, N. Janikashvili et al., "Brief report: Inhibition of interleukin-6 function correctsTh17/Treg cell imbalance in patients with rheumatoid arthritis," Arthritis & Rheumatism, vol. 64, no. 8, pp. 2499-2503, 2012.
46. G. Guggino, A. Giardina, A. Ferrante et al., "The in vitro addition of methotrexate and/or methylprednisolone determines peripheral reduction in Th17 and expansion of conventional Treg and of IL-10 producingTh17 lymphocytes in patients with early rheumatoid arthritis," Rheumatology International, vol. 35, no. 1, pp. 171-175, 2015.
47. K. Nakano, K. Yamaoka, K. Hanami et al., "Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model," The Journal of Immunology, vol. 186, no. 6, pp. 3745-3752, 2011.
48. M. R. Ostadali, G. Ahangari, M. B. Eslami et al., "The detection of dopamine gene receptors (DRD1-DRD5) expression on human peripheral blood lymphocytes by real time PCR," Iranian Journal of Allergy, Asthma, and Immunology, vol. 3, no. 4, pp. 169-174, 2004.
49. A. H. Altamirano-Espinoza, A. González-Hernández, G. Manrique-Maldonado, B. A. Marichal-Cancino, I. Ruiz-Salinas, and C. M. Villalón, "The role of dopamine D2, but not D3 or D4, receptor subtypes, in quinpirole-induced inhibition of the cardioaccelerator sympathetic outflow in pithed rats," British Journal of Pharmacology, vol. 170, no. 5, pp. 1102-1111, 2013.
50. Z. Yang, L. D. Asico, P. Yu et al., "D5 dopamine receptor regulation of phospholipase D," American Journal of Physiology: Heart and Circulatory Physiology, vol. 288, no. 1, pp. H55-H61, 2005.
51. L. Wei, C. Zhang, H. Y. Chen et al., "Dopamine receptor DR2 expression in B cells is negatively correlated with disease activity in rheumatoid arthritis patients," Immunobiology, vol. 220, no. 3, pp. 323-330, 2015.